Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aurinia Pharm Ord (AUPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 597,046
  • Shares Outstanding, K 83,270
  • Annual Sales, $ 170 K
  • Annual Income, $ -23,300 K
  • 36-Month Beta 2.65
  • Price/Sales 3,460.84
  • Price/Cash Flow 0.00
  • Price/Book 3.42

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.76 +4.88%
on 04/24/17
8.19 -13.43%
on 05/15/17
-0.02 (-0.28%)
since 04/21/17
3-Month
3.23 +119.50%
on 02/23/17
10.54 -32.73%
on 03/13/17
+3.69 (+108.53%)
since 02/22/17
52-Week
1.74 +307.47%
on 08/15/16
10.54 -32.73%
on 03/13/17
+4.61 (+185.89%)
since 05/20/16

Most Recent Stories

More News
Lupus Nephritis Market Global Industry Trends, Share, Size, Growth and 2030 Forecasts Report - MarketReportsOnline

PUNE, India, May 22, 2017 /PRNewswire/ --

AUPH : 7.09 (-1.12%)
RHHBY : 34.4300 (+0.39%)
GSK : 43.30 (-0.69%)
BMY : 54.10 (+0.15%)
Lupus Nephritis Market Global Industry Trends, Share, Size, Growth and 2030 Forecasts Report - MarketReportsOnline

The report "Global Lupus Nephritis Market: Industry Analysis & Outlook (2021-2030)" analyses the development of this market, with focus on the U.S, Europe and Japan markets. The major trends, growth drivers...

AUPH : 7.09 (-1.12%)
RHHBY : 34.4300 (+0.39%)
GSK : 43.30 (-0.69%)
BMY : 54.10 (+0.15%)
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

AUPH : 7.09 (-1.12%)
CDTX : 6.75 (-0.74%)
EDIT : 17.45 (-2.57%)
PRGO : 71.36 (+0.81%)
The Growth of the Global Pharmaceuticals Market

A research report by DCAT Connect claims that the total global spend for pharmaceuticals through 2021 will increase by $367 billion on a constant-dollar basis, according to QuintilesIMS. Spending is measured...

AUPH : 7.09 (-1.12%)
THERF : 4.9701 (+2.48%)
CXRX : 1.31 (unch)
QPT.VN : 0.145 (unch)
CRHM : 5.60 (-3.45%)
QPTFF : 0.0922 (-3.96%)
Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?

Investors are always looking for stocks that are poised to beat at earnings season and Aurinia Pharmaceuticals Inc. (AUPH) may be one such company.

AUPH : 7.09 (-1.12%)
What's in the Cards for Repros (RPRX) this Earnings Season?

Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.

RPRX : 0.57 (+1.79%)
AUPH : 7.09 (-1.12%)
IMDZ : 7.65 (+4.79%)
FGEN : 26.60 (-0.56%)
Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings?

Intrexon Corporation (XON) is expected to report first-quarter 2017 results on May 9.

AUPH : 7.09 (-1.12%)
XON : 22.48 (-4.30%)
FGEN : 26.60 (-0.56%)
FCSC : 2.43 (-5.45%)
Aurinia to Present at Bloom Burton & Co. Healthcare Conference

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its Chief Executive Officer, Richard M. Glickman, will present at the Bloom Burton & Co. Healthcare Conference in...

AUP.TO : 9.89 (-6.08%)
AUPH : 7.09 (-1.12%)
Implied Volatility Surging for Aurinia Pharmaceuticals(AUPH) Stock Options

Implied Volatility Surging for Aurinia Pharmaceuticals(AUPH) Stock makes it lucrative to the option traders.

AUPH : 7.09 (-1.12%)
Biotech Stocks on Investors' Radar -- Gilead Sciences, Aurinia Pharma, Mast Therapeutics, and Novavax

Stock-Callers.com today has initiated reports coverage on Gilead Sciences Inc. (NASDAQ: GILD), Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Mast Therapeutics Inc. (NYSEMKT: MSTX), and Novavax Inc. (NASDAQ:...

AUPH : 7.09 (-1.12%)
GILD : 64.36 (+0.20%)
NVAX : 1.02 (-1.92%)
MSTX : 0.13 (-7.14%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Support & Resistance

2nd Resistance Point 7.24
1st Resistance Point 7.16
Last Price 7.09
1st Support Level 7.03
2nd Support Level 6.98

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.